Navigation Links
GeneGo Announces Systems Tox Relationship With Entelos
Date:3/17/2009

ST. JOSEPH, Mich., March 17 /PRNewswire/ -- GeneGo, Inc., the leading provider of pathway data mining & analysis solutions, today announced a license agreement with Entelos of Foster City, CA, a company specializing in predictive technologies, including toxicogenomics and PhysioLab(R) virtual human disease models. GeneGo will use Entelos' DrugMatrix(R) gene expression data to further develop GeneGo's Functional Descriptor predictive toxicology models.

"Access to a comprehensive, pharmacologically-diverse and fully annotated compendium of gene expression data is critical to developing high-performance predictive models," said Richard Brennan, Director of Toxicology at GeneGo. "This is one of the key goals of our MetaTox partnership. DrugMatrix is the largest toxicogenomic database available, and will allow us to apply the lessons we have learned from our participation in the Microarray Quality Control Consortium to expand our collection of biological pathway-based classifiers with toxicity models for a wide variety of adverse drug effects in key target tissues."

"We are very pleased to be working with GeneGo and participating in their MetaTox projects," said Alan Roter, VP of Informatics at Entelos. "GeneGo's unique approach of generating functional descriptors is a great complement to the classifiers and predictive models in DrugMatrix, and we see great benefit to the scientific community using predictive toxicogenomics."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

About Entelos, Inc.

Entelos, Inc. is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, "virtual human" technology, and toxicology reference systems to develop safer and more effective drugs, improve the quality of health-related consumer products, and deliver on the promise of personalized medicine. Entelos provides customized products, technology and research services to global pharmaceutical, health-care, and consumer products companies in safety testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products.

For more information, please visit the company's web site at www.entelos.com


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
2. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
3. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
4. GeneGo Integrates With Cytoscape
5. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
6. GSK Extends GeneGo License and Adds New Products
7. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
8. VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
9. Unilever Extends Their GeneGo MetaCore License
10. Yale Keck Microarray Center Becomes a GeneGo Center of Excellence
11. University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, ā€œClinical Trials Patient Recruitment and Retention Tips.ā€ ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
Breaking Biology News(10 mins):